

PEGASUS: A phase II randomised controlled trial assessing the safety and effectiveness of perampanel, an anti-epileptic drug, in people with brain tumours

Principal Investigators:

Andrew Neal, Terence O'Brien, Patrick Kwan.

Summary of project:

Post-operative seizures occur commonly in patients with gliomas and can have a significant impact on quality of life. There is limited information available on the best anti-epileptic medication for people with brain tumours. However, a new anti-epileptic-drug, called perampanel shows promise for being able to control and prevent seizures in patients with brain tumours.

There are two separate studies in this project for patients with grade II-III supratentorial gliomas.

Study 1 is for patients who experienced a pre-operative seizure. In this study we will compare perampanel and levetiracetam treatment over 12 months after brain tumour surgery.

Study 2 is for patients who did not experience a pre-operative seizure. In study 2 we will compare perampanel and placebo for 4 months after brain tumour surgery and then observe participants for a further 8 months.

Who can take part:

- People aged 18 to 65 years; and
- With a diagnosis of brain tumour (grade II-III glioma) on MRI; and
- An upcoming or recent (within 3 weeks) neurosurgical operation (resection or biopsy of the tumour)

If you think someone may be suitable for this study, please contact Study Coordinators (**Mon-Fri, 8am-5pm**)

Alex: (03) 9076 2598
a.philippou@alfred.org.au

Jack: (03) 9076 2029
J.Germaine@alfred.org.au

Rafael: (03) 9076 2596
ra.smith@alfred.org.au

Emily: (03) 9076 5879
E.Galea@alfred.org.au



theAlfred
Part of AlfredHealth